Nanoparticle Delivery Systems for Substance Use Disorder

Overview

Journal Neuropsychopharmacology

Date 2022 Mar 30

PMID 35351961

Authors

Vishal Kasina

Robert J Mownn

Raman Bahal

Gregory C Sartor

Affiliations

Soon will be listed here.

Abstract

Innovative breakthroughs in nanotechnology are having a substantial impact in healthcare, especially for brain diseases where effective therapeutic delivery systems are desperately needed. Nanoparticle delivery systems offer an unmatched ability of not only conveying a diverse array of diagnostic and therapeutic agents across complex biological barriers, but also possess the ability to transport payloads to targeted cell types over a sustained period. In substance use disorder (SUD), many therapeutic targets have been identified in preclinical studies, yet few of these findings have been translated to effective clinical treatments. The lack of success is, in part, due to the significant challenge of delivering novel therapies to the brain and specific brain cells. In this review, we evaluate the potential approaches and limitations of nanotherapeutic brain delivery systems. We also highlight the examples of promising strategies and future directions of nanocarrier-based treatments for SUD.

Citing Articles

Enhanced Stability and In Vitro Biocompatibility of Chitosan-Coated Lipid Vesicles for Indomethacin Delivery.

Abu Koush A, Popa E, Pricop D, Nita L, Foia C, Pauna A Pharmaceutics. 2025; 16(12.

PMID: 39771553 PMC: 11676990. DOI: 10.3390/pharmaceutics16121574.

A review on lipid and polymeric nano-based 17-β-estradiol delivery systems: advances and challenges.

de Assis Ramos M, Ricardo-da-Silva F, Macedo L, Correia C, Moreira L, Lobenberg R J Pharm Pharm Sci. 2024; 27:13633.

PMID: 39619127 PMC: 11604423. DOI: 10.3389/jpps.2024.13633.

Single and Multitarget Systems for Drug Delivery and Detection: Up-to-Date Strategies for Brain Disorders.

Grosso C, Silva A, Delerue-Matos C, Barroso M Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139848 PMC: 10747932. DOI: 10.3390/ph16121721.

Current trends and future perspectives of stroke management through integrating health care team and nanodrug delivery strategy.

Han X, Qin Y, Mei C, Jiao F, Khademolqorani S, Banitaba S Front Cell Neurosci. 2023; 17:1266660.

PMID: 38034591 PMC: 10685387. DOI: 10.3389/fncel.2023.1266660.

Nucleic acid-based therapeutics for the treatment of central nervous system disorders.

McCartan R, Khorkova O, Volmar C, Wahlestedt C Front Genet. 2023; 14:1250276.

PMID: 37662844 PMC: 10468602. DOI: 10.3389/fgene.2023.1250276.

References

Daley D . Family and social aspects of substance use disorders and treatment. J Food Drug Anal. 2014; 21(4):S73-S76. PMC: 4158844. DOI: 10.1016/j.jfda.2013.09.038. View

Florence C, Luo F, Rice K . The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2020; 218:108350. PMC: 8091480. DOI: 10.1016/j.drugalcdep.2020.108350. View

Douaihy A, Kelly T, Sullivan C . Medications for substance use disorders. Soc Work Public Health. 2013; 28(3-4):264-78. PMC: 3767185. DOI: 10.1080/19371918.2013.759031. View

Sartor G . Epigenetic pharmacotherapy for substance use disorder. Biochem Pharmacol. 2019; 168:269-274. PMC: 6733674. DOI: 10.1016/j.bcp.2019.07.012. View

Pardridge W . The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2(1):3-14. PMC: 539316. DOI: 10.1602/neurorx.2.1.3. View

Salery M, Trifilieff P, Caboche J, Vanhoutte P . From Signaling Molecules to Circuits and Behaviors: Cell-Type-Specific Adaptations to Psychostimulant Exposure in the Striatum. Biol Psychiatry. 2020; 87(11):944-953. DOI: 10.1016/j.biopsych.2019.11.001. View

Nectow A, Nestler E . Viral tools for neuroscience. Nat Rev Neurosci. 2020; 21(12):669-681. PMC: 7808553. DOI: 10.1038/s41583-020-00382-z. View

Kimura S, Harashima H . Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB. Pharmaceutics. 2020; 12(12). PMC: 7765480. DOI: 10.3390/pharmaceutics12121216. View

Ross K, Brenza T, Binnebose A, Phanse Y, Kanthasamy A, Gendelman H . Nano-enabled delivery of diverse payloads across complex biological barriers. J Control Release. 2015; 219:548-559. PMC: 4656048. DOI: 10.1016/j.jconrel.2015.08.039. View

10.

Anselmo A, Mitragotri S . Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019; 4(3):e10143. PMC: 6764803. DOI: 10.1002/btm2.10143. View

11.

Koshimizu Y, Isa K, Kobayashi K, Isa T . Double viral vector technology for selective manipulation of neural pathways with higher level of efficiency and safety. Gene Ther. 2021; 28(6):339-350. PMC: 8221994. DOI: 10.1038/s41434-020-00212-y. View

12.

Segel M, Lash B, Song J, Ladha A, Liu C, Jin X . Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science. 2021; 373(6557):882-889. PMC: 8431961. DOI: 10.1126/science.abg6155. View

13.

Kong Q, Li Y, Yue J, Wu X, Xu M . Reducing alcohol and/or cocaine-induced reward and toxicity via an epidermal stem cell-based gene delivery platform. Mol Psychiatry. 2021; 26(9):5266-5276. PMC: 8380265. DOI: 10.1038/s41380-021-01043-y. View

14.

Wu S, Sanchez C, Samiotaki G, Buch A, Ferrera V, Konofagou E . Characterizing Focused-Ultrasound Mediated Drug Delivery to the Heterogeneous Primate Brain In Vivo with Acoustic Monitoring. Sci Rep. 2016; 6:37094. PMC: 5112571. DOI: 10.1038/srep37094. View

15.

Meng Y, Hynynen K, Lipsman N . Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat Rev Neurol. 2020; 17(1):7-22. DOI: 10.1038/s41582-020-00418-z. View

16.

Dong X . Current Strategies for Brain Drug Delivery. Theranostics. 2018; 8(6):1481-1493. PMC: 5858162. DOI: 10.7150/thno.21254. View

17.

Pardridge W . Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J Control Release. 2007; 122(3):345-8. PMC: 2701689. DOI: 10.1016/j.jconrel.2007.04.001. View

18.

Iwasaki Y, Maie H, Akiyoshi K . Cell-specific delivery of polymeric nanoparticles to carbohydrate-tagging cells. Biomacromolecules. 2007; 8(10):3162-8. DOI: 10.1021/bm700606z. View

19.

Jose S, Sowmya S, Cinu T, Aleykutty N, Thomas S, Souto E . Surface modified PLGA nanoparticles for brain targeting of Bacoside-A. Eur J Pharm Sci. 2014; 63:29-35. DOI: 10.1016/j.ejps.2014.06.024. View

20.

Song E, Gaudin A, King A, Seo Y, Suh H, Deng Y . Surface chemistry governs cellular tropism of nanoparticles in the brain. Nat Commun. 2017; 8:15322. PMC: 5454541. DOI: 10.1038/ncomms15322. View